Clinic business

Astrotech Subsidiary and Cleveland Clinic Expand Breath Analysis Study to Detect Multiple Diseases

AUSTIN, Texas–(BUSINESS WIRE)–Astrotech Corporation (NASDAQ:ASTC) subsidiary, BreathTech Corporation, today announced that it has amended its joint development and option agreement with the Cleveland Clinic to include areas of interest additional. Under the amended agreement, ongoing work around the development of a rapid breath test for COVID-19 will be expanded to use BreathTech’s core mass spectrometry technology to screen for a variety of diseases spanning the whole body. . The project will focus on the detection of bacteremia, respiratory infections such as influenza types A and B and respiratory syncytial virus (RSV), the carriage of Staphylococcus aureusand Clostridioides difficile (It’s hard).

Raed A. Dweik, MD, president of the Cleveland Clinic Respiratory Institute, will continue to lead the study. Dr. Dweik and his research team were among the first to identify that unique metabolites of volatile organic compounds (VOCs) in breath can be used to detect certain diseases. Researchers have successfully identified and published studies regarding unique metabolites of VOCs associated with heart failure, pulmonary arterial hypertension and liver disease.

“We are excited to have the opportunity to expand the scope of our work to advance technology to detect other indicators of disease using breath. We have been working diligently since the COVID-19 pandemic began to refine our mass spectrometry technology to be able to screen for COVID-19 and now we are expanding those efforts to include other diseases,” said Thomas B. Pickens III , general director. BreathTech Officer.

“While our initial focus was on detecting the coronavirus, we now agree that we should extend the study to identify markers of bacterial infections like Staphylococcus aureus and Clostridiodes difficult, as well as other types of viral infections like influenza and RSV, to name a few. We believe this technology has the potential to improve medical diagnostics across the world,” added Dr. Karim Sirgi, Chief Scientific Officer of BreathTech.

About Astrotech

Astrotech (NASDAQ:ASTC) is a mass spectrometry company that initiates, manages and markets scalable businesses based on its innovative core technology through its wholly owned subsidiaries. 1st detection develops, manufactures and sells trace detectors for the security and detection market. AgLAB develops chemical analyzers for the agricultural market. BreathTech is developing a breath analysis tool to enable early detection of lung diseases. Astrotech is headquartered in Austin, Texas. For more information, please visit www.astrotechcorp.com.

About BreathTest-1000™

This press release contains information about our new product under development, BreathTest-1000. Product development involves a high degree of risk and uncertainty, and there can be no assurance that our new products will be successfully developed, achieve intended benefits, receive full marketing clearance or achieve commercial success. Additionally, FDA approval will be required to market BreathTest-1000 in the United States. Obtaining FDA approval is a complex and lengthy process, and there can be no assurance that FDA approval for BreathTest-1000 will be granted in a timely manner or at all.

Forward-looking statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks, trends and uncertainties that could cause actual results to occur. significantly different. of the forward-looking statement. These factors include, but are not limited to, the severity and duration of the COVID-19 pandemic and its impact on the U.S. and global economy, the timing, scope, and effect of other governmental, regulatory, , tax, monetary and public US and international. health responses to the COVID-19 pandemic, the company’s use of proceeds from common stock offerings, whether we can complete the development of our new proprietary products and technologies, whether we can obtain FDA and d other regulatory approvals required to commercialize our products under development in the United States or abroad, whether the market will accept our products and services and whether we will be successful in identifying, completing and integrating acquisitions, and other factors risk and business considerations described in the company’s filings with the Securities and Exchange Commission, including the company’s most recent annual report on Form 10-K. Any forward-looking statements contained herein should be evaluated in light of these important risk factors. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable and are based on reasonable assumptions, there can be no assurance that these assumptions are correct or that any of these expectations will be realized (in whole or not at all) or will prove they were right. In addition, such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the Company’s control, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company undertakes no obligation to correct or update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.